# Drug Discovery Feasibility Assessment: Epigenetic Reprogramming in Aging Neurons
## Executive Summary
These hypotheses represent mechanistically sophisticated models of neuronal aging, but they span a vast range of druggability—from essentially undruggable structural proteins to more tractable enzyme targets and emerging RNA-based modalities. The clinical translation pathway for most of these targets faces substantial obstacles beyond target validation. Below is a systematic evaluation grounded in current pharmaceutical constraints and clinical development realities.
---
## Hypothesis 1: TET2-Mediated 5hmC Loss
### 1. Druggability Assessment
**Target Class:** Fe²⁺/α-ketoglutarate-dependent dioxygenase
**Druggability Score: 2/10 (Very Low)**
TET2 belongs to one of the most challenging enzyme families for small-molecule intervention. The catalytic mechanism requires iron, oxygen, 2-oxoglutarate, and ascorbate—cofactors that are ubiquitous in cells and make selective inhibition or activation extraordinarily difficult. The active site accepts the same cosubstrates as ~60 other 2OG-dependent oxygenases in humans, creating massive selectivity challenges.
**Current approaches considered:**
- **2-Oxoglutarate analogs:** These would need to compete with millimolar intracellular 2OG concentrations—essentially impossible for selective cellular activity
- **Allosteric modulators:** No known allosteric sites on TET enzymes
- **Protein-protein interaction stabilizers:** TET2 functions as part of larger complexes (with O-GlcNAc transferase, etc.); disrupting or enhancing these interactions is theoretically possible but unexplored
- **Epigenetic reader domain targeting:** TET proteins have intrinsically disordered regions but no defined druggable domains
**Critical gap:** TET2 lacks a clear functional pocket suitable for high-affinity small-molecule binding. The enzyme's catalytic mechanism is intrinsically unsuitable for traditional pharmacologic modulation.
### 2. Existing Compounds/Trials
**Status: Essentially non-existent**
| Approach | Development Stage | Sponsor/Program | Comments |
|----------|------------------|-----------------|----------|
| TET2 agonist | None identified | — | No pharma programs publicly disclosed |
| TET2 catalytic modulators | Preclinical at best | Academic labs only | Mostly in oncology (TET2 mutations in MDS) |
| 2OG derivatives | Tool compounds only | Various academic groups | Do not penetrate cells robustly |
| Gene therapy (TET2 expression) | Concept only | — | No AAV construct in development |
The oncology field has explored TET2 inhibition (for hyperactive TET2 in certain cancers) but not activation. No compound has demonstrated selective TET2 activation in neurons.
### 3. Competitive Landscape
**Indirect competition from:**
| Category | Examples | Mechanism | Clinical Stage |
|----------|----------|-----------|----------------|
| Demethylation agents | Azacitidine, Decitabine | DNMT inhibition (not TET) | Approved (oncology) |
| NAD+ precursors | NMN, NR | May indirectly support TET function | Phase 2 (aging) |
| General epigenetic modulators | HDAC inhibitors | Broad chromatin effects | Approved (oncology) |
**Unique positioning:** None of the current approaches directly addresses TET2-mediated 5hmC loss. This is both a gap and a liability—it means no established regulatory pathway, but also no validation of mechanism in neurodegeneration.
### 4. Cost and Timeline Estimate
| Phase | Estimated Duration | Estimated Cost | Key Challenges |
|-------|-------------------|----------------|-----------------|
| Target validation (in vivo) | 3-5 years | $10-15M | Requires novel conditional KO mice, extensive behavioral testing |
| Lead discovery | 5-8 years | $50-80M | No HTS assay validated; may require fragment-based approach |
| Preclinical development | 3-4 years | $30-50M | CNS penetration, selectivity across 60+ 2OG oxygenases |
| Phase I/II | 4-6 years | $80-120M | Unclear patient selection criteria; no validated biomarker |
| **Total to market** | **15-23 years** | **$170-265M** | High attrition at every stage |
**Critical uncertainty:** The field lacks validated biomarkers for 5hmC in CNS. Human brain sampling is impractical; CSF/plasma surrogates don't exist.
### 5. Safety Concerns
| Concern | Severity | Mitigation Strategy |
|---------|----------|---------------------|
| Selectivity across 2OG oxygenases | **Critical** | >60 related enzymes; off-target effects highly likely |
| CNS exposure | **Major** | TET modulators must cross BBB with precise window |
| Hematologic toxicity | **Major** | TET2 loss-of-function linked to myeloid malignancies; gain-of-function unknown |
| Developmental effects | **Moderate** | TET enzymes critical in embryogenesis; chronic dosing concerning |
| Off-target demethylation | **Moderate** | 5hmC changes at unintended genomic loci |
**FDA precedent:** No epigenetic enzyme activator has been approved for CNS indications. The only approved TET-targeting drugs (hypomethylating agents) are for oncology with significant toxicity.
---
## Hypothesis 2: SIRT6 Deficiency
### 1. Druggability Assessment
**Target Class:** NAD⁺-dependent deacetylase/deacylase (sirtuin family)
**Druggability Score: 5/10 (Moderate)**
SIRT6 presents a more tractable profile than TET2 for several reasons:
- **Known active site:** Crystal structures available (PDB: 3KQ4, 3Q96); clear pocket for NAD⁺-acyl ADPreaction intermediate
- **Substrate selectivity:** While challenging, SIRT6 has relatively selective substrates (H3K9ac, H3K56ac, NF-κB p65)
- **Alternative targeting:** Rather than directly activating SIRT6, one can increase NAD⁺ levels or target downstream effectors
**Current approaches:**
- **SIRT6 direct activators:** Several programs existed (GSK's sirtuin activator efforts largely abandoned), but selectivity remains problematic—SIRT1 is the "favorite" with many false-positive activators
- **NAD⁺ precursor supplementation:** NMN, NR, nicotinamide riboside—indirect but clinically advanced
- **PARP inhibitors:** Prevent NAD⁺ consumption; cognitive benefits in early trials
### 2. Existing Compounds/Trials
| Compound | Mechanism | Development Stage | Sponsor |
|----------|-----------|-------------------|---------|
| NMN (nicotinamide mononucleotide) | NAD⁺ precursor | Phase 2 (n=2 trials for aging/cognition) | Various (Intermountain, u. of Washington) |
| NR (nicotinamide riboside) | NAD⁺ precursor | Phase 2 (n=5+ trials for metabolic/aging) | ChromaDex, NIAGEN |
| Elysium Basis (commercial) | NAD⁺ precursor | Marketed supplement | Elysium Health |
| SRT2104 (selective SIRT1 activator) | Direct SIRT1 activation | Discontinued after Phase 2 | GSK |
**Clinical reality check:** NAD⁺ precursors have demonstrated increases in blood NAD⁺ but limited CNS penetration and modest cognitive benefits in trials to date. The Elysium Basis trials showed increased NAD⁺ but no cognitive improvement.
### 3. Competitive Landscape
**Fiercely competitive for NAD⁺:**
| Competitor | Mechanism | Funding | Status |
|------------|-----------|---------|--------|
| ChromaDex | NR supplier | Public (CDXC) | Commercial + Phase 2 trials |
| MetroBiome | NMN formulations | Series A | Early clinical |
| Calico/AbbVie | NAD⁺ biology | >$1B partnership | Preclinical-internal |
| resTORbio | TORC1 inhibition (NAD⁺ pathway) | Failed Phase 3 | Terminated |
**SIRT6-specific landscape:** Essentially no direct competitors. This is both an opportunity and a warning—no one has successfully developed a SIRT6 activator, suggesting either scientific barriers or limited commercial interest.
### 4. Cost and Timeline Estimate
**Path A: Direct SIRT6 activator**
| Phase | Duration | Cost | Notes |
|-------|----------|------|-------|
| Lead optimization | 4-6 years | $40-70M | Must achieve selectivity over SIRT1-5 |
| Preclinical | 3-4 years | $35-50M | Safety, PK/PD, CNS exposure |
| Phase I/II | 4-5 years | $70-100M | Unclear endpoint; aging indication |
| **Total** | **11-15 years** | **$145-220M** | High technical risk |
**Path B: NAD⁺ precursor approach (faster, lower efficacy)**
| Phase | Duration | Cost | Notes |
|-------|----------|------|-------|
| Reformulation/CNS optimization | 2-3 years | $15-25M | Existing compounds, new delivery |
| Phase II | 2-3 years | $30-50M | Biomarker-based selection |
| **Total to Phase II** | **4-6 years** | **$45-75M** | Faster path, but mechanism indirect |
### 5. Safety Concerns
| Concern | Severity | Mitigation |
|---------|----------|------------|
| SIRT6 overexpression | **Moderate** | SIRT6 KO causes neurodegeneration; gain-of-function may promote tumor suppression (SIRT6 is a tumor suppressor) |
| NAD⁺ precursor safety | **Low-Moderate** | Generally safe; niacin contamination causes flushing; unknown long-term effects |
| Selectivity | **Critical** | SIRT1 activation may worsen certain cancers; SIRT2 inhibition neurotoxic |
| Drug-drug interactions | **Moderate** | NMN/NR may affect chemotherapy response, other NAD⁺-dependent pathways |
---
## Hypothesis 3: JARID2 Mislocalization
### 1. Druggability Assessment
**Target Class:** Epigenetic regulatory protein (PRC2 accessory component)
**Druggability Score: 1/10 (Essentially Undruggable)**
This represents the most challenging target in the set. JARID2 is a large (1,200+ amino acid) chromatin-associated protein with:
- **No enzymatic activity:** JARID2 is a structural/recruiting component, not a catalyst
- **Complex post-translational regulation:** Oxidation, phosphorylation, glycosylation—multiple modifications affect its function
- **Protein-protein interaction dependencies:** Functions as part of PRC2 complex; targeting requires disrupting specific interactions while preserving others
- **Undruggable PTM:** "Reversing oxidation" is not a tractable pharmacologic goal
**The fundamental problem:** You cannot drug a protein's oxidation state with small molecules. This mechanism is not currently addressable with any known therapeutic modality.
### 2. Existing Compounds/Trials
| Approach | Status | Comments |
|----------|--------|----------|
| PRC2 inhibitors (EZH2) | Approved (oncology) | Tazemetostat; approved for INI1-deficient tumors |
| JARID2-targeted | None | Not on anyone's radar |
| Antioxidant approaches | Various | N-acetylcysteine, vitamin E trials in aging—failed |
**The irony:** The only clinically relevant compounds targeting this pathway are EZH2 inhibitors (for lymphoma), which would *inhibit* PRC2—the opposite of what the hypothesis proposes.
### 3. Competitive Landscape
**Essentially no competition—and for good reason.** JARID2 has not been linked to any disease in clinical contexts. The mechanism (oxidation → mislocalization → wrong gene targeting) is too speculative and multi-step for drug development investment.
**Adjacent approaches:**
- EZH2 inhibitors (oncolytic, not CNS-relevant)
- General HDAC inhibitors (affect chromatin state broadly)
- BET inhibitors (bromodomain targeting)
### 4. Cost and Timeline Estimate
| Phase | Duration | Cost | Feasibility |
|-------|----------|------|-------------|
| Target validation | 5+ years | $20-30M | Requires novel assays, no clear model |
| Lead discovery | 8+ years | $80-100M+ | Essentially undefined approach |
| Clinical path | ? | ? | No clear regulatory precedent |
| **Total** | **15+ years** | **>$200M** | Essentially non-viable |
**Recommendation:** This hypothesis should be deprioritized for drug development unless novel therapeutic modalities emerge (e.g., protein delivery, targeted protein degradation reversers).
### 5. Safety Concerns
| Concern | Severity | Notes |
|---------|----------|-------|
| PRC2 disruption | **Critical** | EZH2 loss-of-function lethal; gain-of-function linked to B-cell lymphomas |
| Off-target chromatin effects | **Major** | Multiple PRC2 components; specificity impossible |
| Developmental toxicity | **Major** | JARID2 critical in development; chronic exposure concerning |
---
## Hypothesis 4: OGG1 Glycation
### 1. Druggability Assessment
**Target Class:** DNA glycosylase (base excision repair enzyme)
**Druggability Score: 3/10 (Low)**
OGG1 presents a challenging target with multiple structural complications:
- **Enzyme active site:** Glycosylase function requires catalytic residues that are also chemically reactive (cysteine at active site—susceptible to glycation by design)
- **Glycation modification:** The glycation is itself the problem; reversing it pharmacologically would require removing an established chemical modification from protein side chains
- **DNA repair context:** OGG1 must recognize damaged DNA in the context of chromatin—targeting this with small molecules is inherently difficult
**Alternative strategy:** Rather than targeting OGG1 directly, one could target the upstream glycating agent (methylglyoxal) or enhance DNA repair capacity more broadly.
### 2. Existing Compounds/Trials
| Compound | Mechanism | Stage | Comments |
|----------|-----------|-------|----------|
| Pyridoxamine | Methylglyoxal scavenger | Phase 2 (diabetic nephropathy) | May have CNS effects |
| Benfotiamine | Advanced glycation end-product breaker | Widely used supplement | Limited CNS penetration |
| Aminoguanidine | AGEs inhibitor | Discontinued (Phase 3, failed) | Toxicity issues |
| OGG1 activators | Direct activation | None in development | No chemical matter |
**Key insight:** The field has focused on methylglyoxal/AGE pathways rather than OGG1 directly. This suggests OGG1 is not considered rate-limiting.
### 3. Competitive Landscape
| Approach | Competitors | Funding | Status |
|----------|-------------|---------|--------|
| Methylglyoxal scavenging | Pyridoxamine, thiamine derivatives | Moderate academic | Phase 2 trials exist |
| AGE inhibition | Multiple programs | Failed/stalled | Tox concerns |
| DNA repair enhancement | PARP inhibitors | Approved (oncology) | Not CNS-focused |
**No direct OGG1 competitors.** This is a narrow therapeutic angle with limited validation.
### 4. Cost and Timeline Estimate
| Phase | Duration | Cost | Notes |
|-------|----------|------|-------|
| Direct OGG1 approach | 10-15 years | $150-250M | High technical risk |
| Methylglyoxal approach | 5-8 years | $50-80M | Repurposing existing molecules |
| **Methylglyoxal approach total** | **7-10 years** | **$70-120M** | Faster but indirect |
**Risk:** The methylglyoxal approach addresses the upstream cause but may not restore OGG1 function if glycation is irreversible.
### 5. Safety Concerns
| Concern | Severity | Notes |
|---------|----------|-------|
| DNA repair imbalance | **Moderate** | Enhanced repair could allow mutation accumulation |
| OGG1 overexpression | **Unknown** | No safety data; may affect normal repair timing |
| Methylglyoxal intervention | **Low** | Generally safe compounds |
---
## Hypothesis 5: MIR22HG Decoys EZH2
### 1. Druggability Assessment
**Target Class:** Long non-coding RNA (lncRNA)
**Druggability Score: 2/10 (Very Low) for direct targeting; 4/10 (Low-Moderate) for indirect**
This hypothesis proposes targeting a lncRNA—currently among the most challenging therapeutic entities:
- **RNA structure:** LncRNAs are large, structurally undefined, and lack clear functional motifs
- **Subcellular localization:** Nuclear localization (for chromatin-associated lncRNAs) limits ASO efficacy
- **Decoy mechanism:** The "decoy" concept—sequestering EZH2—is mechanistically plausible but not actionable with small molecules
**Alternative targeting:**
- **Antisense oligonucleotides (ASOs):** Can target nuclear RNA but delivery to neurons is challenging
- **Gene therapy:** AAV-based expression of MIR22HG—technically feasible but expensive
- **EZH2 inhibitors:** Would not replicate the decoy function; EZH2 inhibition globally is problematic
### 2. Existing Compounds/Trials
| Approach | Status | Comments |
|----------|--------|----------|
| ASO therapeutics | Approved (various) | Limited CNS success exceptnusinersen (